Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 9/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 5/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | SRC | P12931 | 5/20 | 0.45 |
| ▸ | ABL2 | P42684 | 5/20 | 0.45 |
| ▸ | BTK | Q06187 | 5/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385585 | 0.92 | ADK (0.47) | ADKMTORRAB9AABL1EGFR | |
| SCHEMBL16236916 | 0.84 | MTOR (0.50) | ADKMTORRAB9AABL1EGFR | |
| SCHEMBL29388402 | 0.83 | ADK (0.50) | ADKMTORRAB9AABL1EGFR | |
| SCHEMBL19743546 | 0.82 | MTOR (0.52) | ADKMTORRAB9AABL1EGFR | |
| SCHEMBL30120727 | 0.80 | ABL1 (0.48) | ADKMTORRAB9AABL1EGFR | |
| SCHEMBL16236082 | 0.80 | ABL1 (0.48) | ADKMTORRAB9AABL1EGFR | |
| SCHEMBL29388058 | 0.80 | SRC (0.57) | ADKABL1EGFRSRCBTK | |
| SCHEMBL18393435 | 0.79 | MTOR (0.47) | ADKMTORRAB9AABL1EGFR | |
| SCHEMBL18393434 | 0.79 | MTOR (0.47) | ADKMTORRAB9AABL1EGFR | |
| SCHEMBL24650664 | 0.79 | MTOR (0.54) | ADKMTORRAB9AABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |